Alkermes
Alkermes is a global biopharmaceutical company dedicated to developing medicines that make a difference in the treatment of complex psychiatric and neurological disorders. With a focus on neuroscience, the company leverages its expertise to create innovative medicines, including proprietary commercial products and investigational pipeline candidates, aiming to address unmet patient needs and improve lives.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Compositions and methods for subcutaneous administration of cancer immunotherapy
US-11980652-B2
View DetailsImmunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
US-11945870-B2
View DetailsImmunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
US-11248050-B2
View DetailsCompositions and methods for subcutaneous administration of cancer immunotherapy
US-11246906-B2
View Details
Compositions and methods for subcutaneous administration of cancer immunotherapy
US-11980652-B2
View DetailsImmunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
US-11945870-B2
View DetailsImmunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
US-11248050-B2
View DetailsCompositions and methods for subcutaneous administration of cancer immunotherapy
US-11246906-B2
View DetailsProducts
Proprietary commercial medicines for addiction and serious mental illness (U.S.)
A portfolio of marketed, proprietary medicines manufactured for conditions including alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder.
Proprietary formulation technologies for integration into third‑party medicines
Proprietary long-acting and controlled-release formulation technologies offered for use by third-party pharmaceutical companies in their commercial products.
LYBALVI
LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, indicated for the treatment of schizophrenia and bipolar I disorder in adults.
ALKS 7290
An investigational orexin 2 receptor agonist in development for the treatment of attention-deficit hyperactivity disorder and as an adjunctive treatment to standard antidepressants in major depressive disorder.
LUMRYZ
LUMRYZ is a prescription central nervous system depressant medicine used in people 7 years of age or older to treat cataplexy or excessive daytime sleepiness associated with narcolepsy.
VIVITROL
VIVITROL is an extended-release injectable suspension containing naltrexone, an opioid antagonist indicated for the treatment of alcohol dependence and the prevention of relapse to opioid dependence following opioid detoxification.
Proprietary commercial medicines for addiction and serious mental illness (U.S.)
A portfolio of marketed, proprietary medicines manufactured for conditions including alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder.
Proprietary formulation technologies for integration into third‑party medicines
Proprietary long-acting and controlled-release formulation technologies offered for use by third-party pharmaceutical companies in their commercial products.
LYBALVI
LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, indicated for the treatment of schizophrenia and bipolar I disorder in adults.
ALKS 7290
An investigational orexin 2 receptor agonist in development for the treatment of attention-deficit hyperactivity disorder and as an adjunctive treatment to standard antidepressants in major depressive disorder.
LUMRYZ
LUMRYZ is a prescription central nervous system depressant medicine used in people 7 years of age or older to treat cataplexy or excessive daytime sleepiness associated with narcolepsy.
VIVITROL
VIVITROL is an extended-release injectable suspension containing naltrexone, an opioid antagonist indicated for the treatment of alcohol dependence and the prevention of relapse to opioid dependence following opioid detoxification.
Services
Financial and administrative support for investigator-initiated clinical research and clinical trial execution.
Support for independent accredited educational activities in therapeutic focus areas.
Electronic procurement platform for supplier registration, eSourcing, supplier management and procure-to-pay processes.
U.S. medical information phone and email support, plus a dedicated portal for healthcare professionals and mechanisms to report adverse events and product complaints.
Process and policy framework for evaluating patient eligibility for access to investigational medicines outside clinical trials.
Engagement and formation of partnerships for development, manufacturing and commercialization of medicines.
Financial and administrative support for investigator-initiated clinical research and clinical trial execution.
Support for independent accredited educational activities in therapeutic focus areas.
Electronic procurement platform for supplier registration, eSourcing, supplier management and procure-to-pay processes.
U.S. medical information phone and email support, plus a dedicated portal for healthcare professionals and mechanisms to report adverse events and product complaints.
Process and policy framework for evaluating patient eligibility for access to investigational medicines outside clinical trials.
Engagement and formation of partnerships for development, manufacturing and commercialization of medicines.
Expertise Areas
- Neuroscience drug discovery and development
- Clinical trial management (Phase 1–3 and long-term safety studies)
- Formulation development for long-acting injectables and oral controlled-release dosage forms
- Molecular design and computational chemistry
Key Technologies
- Long-acting injectable delivery systems
- Oral controlled-release solid-dosage technologies (delayed/extended/pulsatile/chrono-timed)
- Nanocrystal / particle-based formulation
- Molecular dynamics simulation
News & Updates
Alkermes to participate in the 46th Annual Goldman Sachs Global Healthcare Conference on June 2, 2025.
Alkermes highlights data from its psychiatry portfolio at Spring 2025 scientific conferences.
Alkermes to present new research related to ALKS 2680 at SLEEP 2025.
Alkermes to participate in the 46th Annual Goldman Sachs Global Healthcare Conference on June 2, 2025.
Alkermes highlights data from its psychiatry portfolio at Spring 2025 scientific conferences.
Alkermes to present new research related to ALKS 2680 at SLEEP 2025.